Ryan Bloomer - Elevation Oncology Senior Operations
| ELEVDelisted Stock | USD 0.37 0.00 0.00% |
Executive
Ryan Bloomer is Senior Operations of Elevation Oncology
| Phone | 716 371 1125 |
| Web | https://elevationoncology.com |
Elevation Oncology Management Efficiency
The company has return on total asset (ROA) of (0.2986) % which means that it has lost $0.2986 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7832) %, meaning that it created substantial loss on money invested by shareholders. Elevation Oncology's management efficiency ratios could be used to measure how well Elevation Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Elevation Oncology currently holds 31.13 M in liabilities. Elevation Oncology has a current ratio of 6.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Elevation Oncology's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Peter McNamara | Tectonic Therapeutic, | 53 | |
| Jim Murray | Tscan Therapeutics | N/A | |
| Pramod Gupta | Unicycive Therapeutics | 65 | |
| MPH MD | Tscan Therapeutics | 49 | |
| Barry MS | Tectonic Therapeutic, | N/A | |
| Shrikanta MD | Tscan Therapeutics | N/A | |
| Ray MBA | Tscan Therapeutics | N/A | |
| Zoran JD | Tscan Therapeutics | 55 | |
| Stephen Camiolo | Tscan Therapeutics | N/A | |
| John Diener | Tectonic Therapeutic, | N/A | |
| Heather Savelle | Tscan Therapeutics | N/A | |
| Cagan Gurer | Tscan Therapeutics | N/A | |
| Leiden MBA | Tscan Therapeutics | 41 | |
| Daniel MBA | Tectonic Therapeutic, | 43 | |
| Michael McNamara | In8bio Inc | N/A | |
| Marcella MD | Tectonic Therapeutic, | 61 | |
| Melissa Beelen | In8bio Inc | N/A | |
| Anthony MD | Tectonic Therapeutic, | N/A | |
| MS MD | Tectonic Therapeutic, | 62 | |
| Douglas MBA | Unicycive Therapeutics | 64 | |
| Christian Cortis | Tectonic Therapeutic, | 56 | |
Management Performance
| Return On Equity | -0.78 | |||
| Return On Asset | -0.3 |
Elevation Oncology Leadership Team
Elected by the shareholders, the Elevation Oncology's board of directors comprises two types of representatives: Elevation Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elevation. The board's role is to monitor Elevation Oncology's management team and ensure that shareholders' interests are well served. Elevation Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elevation Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Ferra, Chief Officer | ||
| Valerie MD, Chief Officer | ||
| RPh PharmD, President, Founder | ||
| Ryan Bloomer, Senior Operations | ||
| Biren Shah, Senior Development | ||
| Brian Sullivan, VP Devel | ||
| Candice Masse, Senior Relations | ||
| Robert Yang, Senior Counsel | ||
| PMP CPA, CFO Secretary | ||
| David Dornan, Chief Officer |
Elevation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elevation Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | |||
| Return On Asset | -0.3 | |||
| Current Valuation | (27.78 M) | |||
| Shares Outstanding | 59.25 M | |||
| Shares Owned By Insiders | 0.35 % | |||
| Shares Owned By Institutions | 59.72 % | |||
| Number Of Shares Shorted | 2.08 M | |||
| Price To Earning | 0.16 X | |||
| Price To Book | 0.46 X | |||
| EBITDA | (44.7 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in commodities. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Elevation Stock
If you are still planning to invest in Elevation Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Elevation Oncology's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |